Reply letter to “safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance”

Rebeca Saborido-Fiañoa Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain

https://orcid.org/0000-0003-2972-5032

Nazareth Martinón-Torresa Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain

Vanesa Crujeiras-Martineza Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain

Maria Luz Couceb Unit of Diagnosis and Treatment of Congenital Metabolic Diseases, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, Spain

https://orcid.org/0000-0003-4861-9905

Rosaura Leisa Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, University Clinical Hospital, Santiago de Compostela, SpainCorrespondence[email protected]

https://orcid.org/0000-0002-0540-4210

References

Urru SAM, Maines E, Campomori A, Soffiati M. Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance. Hum Vaccin Immunother. 2021:1-3. doi:10.1080/21645515.2021.1943992.
Google Scholar
European Medicines Agency. First COVID-19 vaccine approved for children aged 12 to 15 in EU. News May 28, 2021. https://www.ema.europa.eu/en/news/first-covid-19-vaccine-approved-children-aged-12-15-eu.
Google Scholar
Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic. May, 2021. https//www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use
Google Scholar
European Medicines Agency. EMA evaluating the use of COVID-19 Vaccine Moderna in young people aged 12 to 17. News, June 06, 2021. https://www.ema.europa.eu/en/news/ema-evaluating-use-covid-19-vaccine-moderna-young-people-aged-12-17
Google Scholar
Garrido C, Curtis AD, Dennis M, Pathak SH, Gao H, Montefiori D, Tomai M, Fox CB, Kozlowski PA, Scobey T, et al. Sars Cov 2 vaccines elicit durable immune responses in infant Rhesus macaques. Sci Immunol. 2021 15;6(60):eabj3684. doi:10.1126/sciimmunol.abj3684
PubMed Web of Science ®Google Scholar
Gallo G, Mel R, Ros E, Filia A. Guida alle controindicazioni alle vaccinazioni (aggiornamento 2018). Roma (Italy): Istituto Superiore di Sanità; 2019. (Rapporti ISTISAN 19/3).
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Reply letter to “safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance”

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reply letter to “safety of SARS-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance”

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date